From GlobeNewswire: 2024-11-21 16:05:00

CAMP4 Therapeutics completed an IPO, raising $82.1M. Phase 1 study of CMP-CPS-001 is progressing, with safety data expected in Q1 2025. A collaboration with BioMarin worth over $370M was established to target regRNAs for genetic diseases. Financial results for Q3 2024 were reported, with $2.5M in cash and $13.5M net loss.

The IPO raised approximately $82.1M for CAMP4. A strategic research collaboration with BioMarin valued at over $370M was announced. CMP-CPS-001 received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA. Safety data for SAD expected in Q1 2025, followed by MAD biomarker efficacy data in H2 2025.

CAMP4 Therapeutics reported financial results for Q3 2024, ending with $2.5M in cash. R&D expenses were $9.7M, G&A expenses were $3.8M, and net loss was $13.5M. The company is well-positioned for continued growth and development.

CAMP4 is a biotechnology company developing regRNA-targeting therapeutics. The company’s approach aims to upregulate gene expression to restore healthy protein levels in genetic diseases. The proprietary RAP Platform™ enables the mapping of regRNAs to target specific genetic conditions. Learn more at www.CAMP4tx.com.



Read more at GlobeNewswire:: CAMP4 Reports Third Quarter 2024 Financial Results